University of Tokyo Edge Capital joined a second close that expanded the cell therapy developer's series B round by an extra $11m.

The Tata-backed personalised cancer therapy developer has completed a $40m round that increased its funding to $76m altogether.

Celgene joined investors including Alexandria Venture Investments to expand the cell therapy developer's series B round by an extra $11m.

Existing backer Otsuka Holdings has agreed to acquire the remaining shares in portfolio company Recor, the creator of a device that treats hypertension.

Hebrew University of Jerusalem has spun out NewStem to develop a stem cell-based approach for predicting whether a cancer patient is likely to respond to chemotherapy.

The robotic exoskeleton producer has raised an initial $81.9m for the fund, which has secured several corporate LPs.

Spun out of University of Cape Town, Nisonic hopes to use ultrasound to provide a better method for tracking brain pressure to monitor conditions such as stroke, brain tumours and head trauma.